Frontera News

Frontera Therapeutics’ FT-002 Achieves Orphan Drug Designation from the U.S. FDA for Inherited Retinal Dystrophies

BEDFORD, Mass., and Suzhou, China, January 23, 2024 — Frontera Therapeutics announces that its pioneering AAV gene therapy product, FT-002, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of Inherited Retinal Dystrophies (IRD) caused by RPGR gene variants. About Orphan Drug Designation Orphan Drug Designation, granted …

Frontera Therapeutics’ FT-002 Achieves Orphan Drug Designation from the U.S. FDA for Inherited Retinal Dystrophies Read More »

Preliminary Clinical Study Results of Frontera Therapeutics FT-002 Injection Presented at APVRS Congress

Hongkong, China, Decemeber 8th, 2023 – Preliminary clinical study results of FT-002, an AAV gene therapy treatment of Frontera Therapeutics, a potential first in class therapy for the treatment of XLRP, were reported at the 16th Asia-Pacific Vitreo-Retina Society, APVRS, 2023). Professor Sui Ruifang from Peking Union Medical College Hospital was invited to participate in …

Preliminary Clinical Study Results of Frontera Therapeutics FT-002 Injection Presented at APVRS Congress Read More »

Frontera Therapeutics Initiates Phase II Clinical Trial for FT-001 in Hereditary Retinopathy Treatment

Beijing, China, Decemeber 3rd, 2023 – Frontera Therapeutics (Suzhou) Co., Ltd. (hereinafter referred to as Frontera Therapeutics) convened a meeting in Beijing on December 3 to conclude the Phase I clinical study of FT-001, and initiate the Phase II clinical study. The meeting was attended by esteemed clinical experts, including Professor Sui Ruifang, Professor Yu …

Frontera Therapeutics Initiates Phase II Clinical Trial for FT-001 in Hereditary Retinopathy Treatment Read More »

Frontera Therapeutics announces CDE clearance to initiate clinical trial of a First-in-class gene therapy for the treatment of RPGR-associated X-linked Retinitis Pigmentosa

BEDFORD, Mass., and SHANGHAI, China, Nov 6th, 2023 – Frontera Therapeutics (Suzhou) Co., Ltd (referred to as Frontera) announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has given clearance of the Investigational New Drug (IND) application to begin a clinical trial of an innovative gene therapy drug, FT-002, for …

Frontera Therapeutics announces CDE clearance to initiate clinical trial of a First-in-class gene therapy for the treatment of RPGR-associated X-linked Retinitis Pigmentosa Read More »